Literature DB >> 27366570

Postoperative Respiratory Failure in a Patient with Undiagnosed Myastenia Gravis.

Funda Özel1, Ali Aydın Altunkan1, Mustafa Azizoğlu1.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease caused by the development of antibodies against the nicotinic acetylcholine receptor. There is hypersensitivity against non-depolarizing muscle relaxants in these patients. Sugammadex eliminates the effects of steroid non-depolarizing muscle relaxants, such as rocuronium and vecuronium, by selectively encapsulating their molecules. In this case report, we present a case of recurarization and respiratory failure after the use of sugammadex and rocuronium in a patient with preoperatively undiagnosed myasthenia gravis.

Entities:  

Keywords:  Myasthenia gravis; respiratory failure; rocuronium; sugammadex

Year:  2016        PMID: 27366570      PMCID: PMC4894196          DOI: 10.5152/TJAR.2016.03274

Source DB:  PubMed          Journal:  Turk J Anaesthesiol Reanim        ISSN: 2149-276X


  5 in total

1.  Recurarization after sugammadex reversal in an obese patient.

Authors:  Frédérique Le Corre; Salmi Nejmeddine; Chérif Fatahine; Claude Tayar; Jean Marty; Benoît Plaud
Journal:  Can J Anaesth       Date:  2011-07-13       Impact factor: 5.063

Review 2.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

3.  Failure of sugammadex to reverse rocuronium-induced neuromuscular blockade: a case report.

Authors:  José R Ortiz-Gómez; Francisco J Palacio-Abizanda; Inocencia Fornet-Ruiz
Journal:  Eur J Anaesthesiol       Date:  2014-12       Impact factor: 4.330

4.  The use of sugammadex in a patient with myasthenia gravis.

Authors:  C Unterbuchner; H Fink; M Blobner
Journal:  Anaesthesia       Date:  2010-01-23       Impact factor: 6.955

Review 5.  Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Authors:  Stefan Josef Schaller; Heidrun Fink
Journal:  Core Evid       Date:  2013-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.